LLY
ELI LILLY & Co
NYSE · Healthcare · Drug Manufacturers - General · US
$1,152.22
−0.02%Jun 23, 2026, 00:00 UTC
Daniel M. Skovronsky, M.D., Ph.D. was appointed to the Board of Directors of Illumina, Inc. effective June 16, 2026.
Jun 19, 2026, 17:58 UTC
ARK Invest increased its stake in Tesla and Snowflake while reducing its stake in Roku on June 18.
Jun 18, 2026, 09:55 UTC
ARK Invest added $46 million worth of Eli Lilly stock on June 17.
Source:May 31, 2026, 12:01 UTC
Eli Lilly announced Phase 3 LIBRETTO-432 clinical trial results for Retevmo (selpercatinib) as adjuvant therapy for early-stage RET fusion-positive lung cancer, showing an 83% reduction in risk of disease recurrence or death.
Source:
← PreviousPage 2